Trial reportFrontiers in surgery2025
Factors associated with major complications defined by Clavien-Dindo classification 3-5 after liver transplantation: a prospective multicenter cohort study.
Trial report in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04405518 (Impact of Two Thromboelastometry-guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation. a Multicenter, Randomized Trial. TROMBOFIBtrial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Two Thromboelastometry-guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation. a Multicenter, Randomized Trial. TROMBOFIBtrial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to explore factors preoperative and intraoperative, associated with Clavien-Dindo classification 3-5 (CDC 3-5) after LT. Methods: Secondary analysis of multicenter prospective cohort data for 305 consecutive patients. European Clinical Trials Database -EudraCT 2018-002510-13. The primary outcome was the incidence of CDC 3-5 complications recorded during the ICU stay. We used a log-binomial regression model to evaluate associations. Results: Cardiac-death donors provided 30.16% of grafts. Vena cava preservation was performed in nearly all patients, and a temporary portacaval shunt was used in 41.91%. Intraoperative red blood cell (RBC) transfusion was required in 51.48%, and 27.37% required additional transfusions within 24 h of LT. CDC 3-5 status occurred in 97 patients (31.80%, 95% CI, 26.58%-37.03%). Thrombotic events occurred in 19 patients (6.25%): 6 in portal veins, 5 in hepatic arteries, 2 in mesenteric veins, and 6 in deep veins. Two patients were retransplanted. Twenty-two (7.21%) required reinterventions; 2 were retransplanted; and 20 (6.57%) were readmitted to the ICU. Adjusted relative risk (aRR) calculation found associations with a MELD score >23 (aRR, 1.92; 95% CI, 1.28-2.8), baseline hemoglobin concentration (aRR, 0.98; 95% CI, 0.97-0.99), zero RBC transfusion (aRR, 0.37; 95% CI, 0.28-0.72), an RBC transfusion cut point of >2.5 (aRR, 1.96; 95% CI, 1.29-2.96), PRS (aRR, 2.11; 95% CI, 1.43-3.10), and fibrinogen administration (aRR, 1.07; 95% CI, 1.05-1.09). We found no associations with temporary portocaval shunt (aRR, 1.02; 95% CI (0.7-1.48), cold and warm ischemia times or surgical time and intraoperative fluid administration. Conclusion: We conclude that PRS at reperfusion of the liver graft and the volume of RBCs transfused are the main modifiable factors that influence major complications reflected by CDC 3-5 status after LT. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT04405518.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.